CDKN2A and neoplasm: Indeed, the corresponding CDKN2A product (p16 protein) was reported to act by blocking progression through the cell cycle [3], [4] and to suppress tumor invasion and metastasis by acting as an inhibitor of expression of various matrix metalloproteinases in tumor cells [6]–[8].